Pharma

Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.

Adds macrocyclic peptide platform to broaden immunology toolbox, enabling oral and long‑acting drug development; deal up to $1.15 billion.

Post hoc ESSENCE subgroup (n=106) showed improvements in ALT, AST, FAST, ELF and PRO‑C3 at week 72 versus placebo; findings presented at AASLD 2026.

Phase 3 ALKIVIA met primary and key secondary endpoints in combined IMNM and DM; argenx will file an sBLA for IMNM by end‑2026 following Breakthrough Therapy designation.

Exit interviews found 96% reported mouth dryness and linked symptom relief to better daily functioning; Phase 2 saliva gains with nipocalimab helped shape the Phase 3 DAFFODIL design.

Phase 3 ICONIC‑PsA 1: 58% ACR20 vs 41% placebo at Week 16 for oral IL‑23R blocker; responses increased by Week 24 and safety was consistent.

Positive opinions for multiple veterinary authorisations including Scovella (velagliflozin) under the limited market framework; vaccine variations; JIACRA V adoption and regulatory consultations.

Real‑world cohorts showed Wegovy 2.4 mg was associated with larger reductions in body weight, AST/ALT, and HbA1c versus resmetirom or no semaglutide in adults with MASH.

Eligible patients can obtain Zepbound (tirzepatide) and Foundayo (orforglipron) via Hims & Hers telehealth with self-pay prices from $149/month for Foundayo and $299/month for Zepbound.

Subcutaneous bispecific (amivantamab + hyaluronidase) approved for adults with recurrent/metastatic head and neck squamous cell carcinoma after platinum and anti‑PD‑(L)1 therapy.